One of the primary objectives of KDIGO is the improvement of medical care for patients with chronic kidney disease (CKD). In that respect, the management of hypertension, a common disorder in these patients, is critical. High blood pressure (BP) is closely related to adverse kidney and cardiovascular (CV) outcomes in CKD. As a result, KDIGO published a guideline on the management of hypertension in CKD in 2012. The guideline was derived from a significant effort by the Work Group to summarize the evidence in this topic available through 2011. Since 2011, new evidence has emerged which has important implications that should be considered for integration in the guideline. Therefore, KDIGO convened a Controversies Conference to examine this new evidence as it relates to management and treatment of hypertension in CKD.

The KDIGO Controversies Conference on Blood Pressure in CKD gathered a global panel of multidisciplinary clinical and scientific expertise to identify key issues relevant to the updating of the 2012 KDIGO BP guideline. The objective of this conference was to assess the current state of knowledge related to the optimal means for measuring BP; management of hypertension in CKD patients with and without diabetes, the elderly, as well as the pediatric and kidney transplant subpopulations.

Alfred K. Cheung, MD (Chief, Division of Nephrology & Hypertension, University of Utah Health, USA) and Johannes F. E. Mann, MD, (KfH Kidney Center, Munich & Dept. of Nephrology & Hypertension, University of Erlangen-Nuremberg, Germany) co-chaired this conference.

Below is a recorded webinar on Blood Pressure in CKD featuring Tara Chang and Sheldon Tobe, both of whom were part of the Steering Committee for the KDIGO Controversies Conference on Blood Pressure in CKD. The webinar was developed in collaboration with the International Society of Nephrology, and held on March 9, 2018.